Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27847551 | 0.93 | ALDH1A1 (0.56) | ALDH1A1PKMTDP1ATMMAPT | |
| SCHEMBL2998222 | 0.93 | ALDH1A1 (0.56) | ALDH1A1PKMTDP1ATMMAPT | |
| SCHEMBL12466651 | 0.89 | MAPT (0.53) | ALDH1A1PKMTDP1ATMMAPT | |
| SCHEMBL396110 | 0.88 | ALDH1A1 (0.64) | ALDH1A1PKMTDP1ATMMAPT | |
| SCHEMBL3410406 | 0.85 | ALDH1A1 (0.46) | ALDH1A1PKMTDP1ATMMAPT | |
| SCHEMBL12788079 | 0.84 | ALDH1A1 (0.66) | ALDH1A1PKMMAPTL3MBTL1KCNMA1 | |
| SCHEMBL3363361 | 0.82 | MAPT (0.50) | ALDH1A1PKMTDP1ATMMAPT | |
| SCHEMBL15498651 | 0.82 | ALDH1A1 (0.64) | ALDH1A1PKMMAPTPDK1MAPK1 | |
| SCHEMBL624054 | 0.82 | ALDH1A1 (0.64) | ALDH1A1PKMTDP1MAPTL3MBTL1 | |
| SCHEMBL30558592 | 0.82 | ALDH1A1 (0.64) | ALDH1A1PKMMAPTPDK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1523473-B1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-7858616-B2 | Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-12-28 | — | — | US | disclosed |
| EP-1996590-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20090197876-A1 | INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-06 | — | — | US | disclosed |
| US-7547703-B2 | Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-06-16 | — | — | US | disclosed |
| EP-1551830-B1 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| CN-101400680-A | Spiroindolinone derivatives | HOFFMANN LA ROCHE (CH) | 2009-04-01 | — | — | CN | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-2020408-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | Sugen, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000059883-A2 | METHOD FOR PRODUCING N-ARYL-AZA-HETEROCYCLES IN THE PRESENCE OF CESIUM CARBONATE | Gödecke GmbH (DE) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
| US-6051593-A | USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN TYROSINE KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER | SUGEN, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0984930-A1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | Sugen, Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999061422-A1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1998050356-A1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197876-A1 | INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | KDR, FLT1, ERBB2 | ALDH1A1 2738/4885PKM 605/4885TDP1 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.